Pioneering a New Class of Vaccines for Global Unmet Medical Needs
Each year, influenza causes up to 700,000 deaths and close to one billion symptomatic cases worldwide. Despite decades of vaccine development, current influenza vaccines average below 40% effectiveness in elderly populations, way below the efficacy target set by WHO at 70%.
Our Pipeline
OVX033 – Universal Sarbecovirus Vaccine Candidate
Facts about the
Coronavirus
Even before the current Covid-19 pandemic, the world has grappled with pandemic coronaviruses, experiencing three outbreaks over the last twenty years alone that have claimed the lives of millions around the globe. The most recent pandemic has shown that vaccine technologies are effective and critical to protecting lives, however current surface antigen-specific approaches are limited against highly mutating viruses.
Number of coronavirus outbreaks
over the past 20 years
over the past 20 years
0
Currently commercialized vaccines target the constantly evolving spike surface antigens with the aim to generate B-cell responses. Osivax is creating a revolutionary universal sarbecovirus vaccine which will uniquely empower both the B-cell immune response and the T-cell immune response.
Osivax is engineering a vaccine (OVX033) that targets the virus’ nucleocapsid, an internal and invariant antigen. This target can be transformed into a highly immunogenic antigen when enabled by the oligoDOMTM technology and is expected to provide universal breadth of protection against all current and future sarbecoviruses.
Osivax builds on the experience gained through the development of OVX836 in influenza which facilitates the development and preclinical proof-of-concept of OVX033 in less than one year. OVX033 is being evaluated in a First-In-Human trial at the Vaccine Clinical Investigator Center Cochin-Pasteur, APHP.
Osivax is engineering a vaccine (OVX033) that targets the virus’ nucleocapsid, an internal and invariant antigen. This target can be transformed into a highly immunogenic antigen when enabled by the oligoDOMTM technology and is expected to provide universal breadth of protection against all current and future sarbecoviruses.
Osivax builds on the experience gained through the development of OVX836 in influenza which facilitates the development and preclinical proof-of-concept of OVX033 in less than one year. OVX033 is being evaluated in a First-In-Human trial at the Vaccine Clinical Investigator Center Cochin-Pasteur, APHP.